oHSV name | Genetic modification | Descrption | Clinical application |
---|---|---|---|
Dlsptk | TK−(UL23) | Internal deletion within UL23 | Malignant human gliomas |
hrR3 | UL39 | Insertion of LacZ (encodes β-galactosidase) in UL39 | Pancreatic cancer; colon carcinoma; liver cancers |
HSV1716 | ICP34.5 | Deletion in both copies of ICP34.5 | Glioblastoma multiforme; anaplastic astrocytoma; oral squamous cell carcinoma |
R3616 | ICP34.5 | Deletion of two copies of ICP34.5 | Pancreatic cancer; colon carcinoma |
G207 | ICP34.5 | Deletions of two copies of the ICP34.5; insertion of an Escherichia coli LacZ | Prostate adenocarcinoma; glioblastoma; hepatocellular carcinoma; colorectal cancer |
R7020 (NV1020) | UL23, UL55, UL56, RL1, RL2, RS1 | Deletion of UL23, as well as the region encoding UL55, UL56, and one copy of RL1, RL2, and RS1 (though not the RS1 promoter) | Pancreatic cancer; colon carcinoma; bladder cancer; pleural cancer |
G47Δ | RL1, UL39, US11, US12 | Deletion of the overlapping US11 promoter/US12 region, putting expression of the normally late US11 gene under the immediate early US12 promoter | Prostate adenocarcinoma; glioblastoma; rectal cancer; nasopharyngeal carcinoma; breast cancer |
OncoVexGM-CSF | ICP34.5 and ICP47 | Deletion of two copies of ICP34.5 gene and the viral ICP47 genes; insertion of GM-CSF | Breast cancer; head and neck cancer; gastrointestinal cancers; malignant melanoma |
HF10 | UL53, UL54, UL55, UL56 | Spontaneous deletion of UL56 as well as duplication of UL53, UL54, and UL55 | Breast cancer; malignant melanoma; pancreatic cancer |
DM33 | ICP34.5 | Deletions of γ-34.5 and LAT gene | Human gliomas and glioma cell line |